Results 261 to 270 of about 914,658 (345)

The Finite Absorption Time Concept Guiding Model Informed Drug & Generics Development in Clinical Pharmacology. [PDF]

Pharm Res
Macheras P, Tsekouras AA, Sánchez-Herrero S, Kosmidis K.   +3 more
europepmc   +1 more source

Expanding Chemical Space of Nucleic Acid Nanoparticles for Tunable Antiviral‐Like Immunomodulatory Responses and Potent Adjuvant Activity

Advanced Functional Materials, EarlyView.
We introduce a nucleic acid nanoparticle (NANP) platform designed to be rrecognized by the human innate immune system in a regulated manner. By changing chemical composition while maintaining constant architectural parameters, we identify key determinants of immunorecognition enabling the rational design of NANPs with tunable immune activation profiles
Martin Panigaj, Hannah S. Newton, Jian Wang, Laxmi Pandey, Yelixza I. Avilla, Phong Nguyen, Morgan Chandler, Justin Halman, Yasmine Radwan, Stephanie Smith, Elijah Edmondson, Simone Difilippantonio, Chelsea Sanders, Bao Tran, Yongmei Zhao, Shaojun Xie, Edward Cedrone, Barry W. Neun, Meni Wanunu, Nikolay V. Dokholyan, Marina A. Dobrovolskaia, Kirill A. Afonin   +21 more
wiley   +1 more source

Journal of Population Therapeutics and Clinical Pharmacology

Marryam Rauf, Ahmed Hamad, Nusrum Iqbal, Bakhtawar Hasnain, Ibraheem Rashid Shah, Naser Faiz Uddin, Hiba Butt   +6 more
openalex   +2 more sources

Editorial: Advances in perinatal and neonatal clinical pharmacology. [PDF]

Front Pharmacol
Gade C, Andersen JT, Futtrup TB, Lausten-Thomsen U.   +3 more
europepmc   +1 more source

A Vascular Microphysiological Model of Lung Fibrosis Reveals That Myofibroblasts and IPF Patient‐Derived Fibroblasts Impair Angiogenesis and Vasculogenesis

Advanced Functional Materials, EarlyView.
A microphysiological lung fibrosis model recapitulates myofibroblast–vascular interactions. Induced myofibroblasts and patient‐derived IPF fibroblasts impair angiogenesis and increase vascular permeability via TGF‐β1–driven signaling. Pharmacological interventions with SB 431542 and VEGF supplementation restore vascular morphology and barrier function.
Elena Cambria, Adriana Blazeski, Eunkyung Clare Ko, Tran Thai, Shania Dantes, David A. Barbie, Sarah E. Shelton, Roger D. Kamm   +7 more
wiley   +1 more source

Recommended Phase II Doses of Talquetamab in Patients With Relapsed/Refractory Multiple Myeloma From MonumenTAL-1: Clinical Pharmacology Results. [PDF]

Clin Pharmacol Ther
Gong J, Zhou J, Yuan D, Ma X, Vishwamitra D, Hilder B, Masterson TJ, Tolbert J, Renaud T, Heuck C, Kane C, Samtani MN, Girgis S, Haddish-Berhane N, Berdeja J, Krishnan A, Ouellet D.   +16 more
europepmc   +1 more source

FORMATION OF SKILLS FOR CONDUCTING PRE-CLINICAL RESEARCH IN STUDENTS OF VORONEZH STATE MEDICAL UNIVERSITY NAMED AFTER N. N. BURDENKO AT THE DEPARTMENT OF PHARMACOLOGY [PDF]

Berezhnova T.A., И В Коваленко, Ekaterina S. Natarova, В. И. Харина, Yuliya A. Trubchanina, Е.А. Лунева   +5 more
openalex   +1 more source

A Smart Bio‐Battery Facilitates Diabetic Bone Defect Repair Via Inducing Macrophage Reprogramming and Synergistically Modulating Bone Remodeling Coupling

Advanced Functional Materials, EarlyView.
This research presents a novel implantable bio‐battery, GF‐OsG, tailored for diabetic bone repair. GF‐OsG generates microcurrents in high‐glucose conditions to enhance vascularization, shift macrophages to the M2 phenotype, and regulate immune responses.
Nanning Lv, Haifu Sun, Wenxiang Tang, Yonggang Li, Zhonglai Qian, Lihui Hong, Chong Chen, Hongye Li, Jiaxiang Bai, Yusen Qiao, Mingming Liu   +10 more
wiley   +1 more source

Clinical pharmacology of thiopropium bromide

Терапевтический архив, 2003
A N Tsoi, V V Arkhipov
doaj